ARTICLE | Clinical News
Gamunex-C regulatory update
October 25, 2010 7:00 AM UTC
FDA approved subcutaneous and IV formulations of Gamunex-C immune globulin to treat primary immunodeficiency. The agency also approved IV Gamunex-C to treat chronic inflammatory demyelinating polyneur...